Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jaime Cancel

Pulmonary Disease Port Charlotte, FL Medical Doctor

NPI 1689778706 CMS profile 303802

4235 Kings Highway, Suite 103, Port Charlotte, FL 33980

Open in the dashboard

General payments

$17,127

866 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jaime Cancel of Port Charlotte, FL is reported in the CMS Open Payments database as having received $17,127 across 866 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,473 165
2024 General $3,085 147
2023 General $2,960 153
2022 General $2,877 130
2021 General $2,612 144
2020 General $1,068 70
2019 General $1,052 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaime Cancel
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jaime Cancel were reported at $3,473. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jaime Cancel Pulmonary Disease median Middle half National median
2019 $1,052 $377 $109–$1,340 $163
2020 $1,068 $230 $56–$907 $114
2021 $2,612 $269 $68–$1,072 $132
2022 $2,877 $390 $100–$1,457 $149
2023 $2,960 $419 $114–$1,659 $160
2024 $3,085 $476 $123–$1,818 $164
2025 $3,473 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,025 136 payments
  2. GlaxoSmithKline, LLC. $2,869 201 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,722 81 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,694 90 payments
  5. Regeneron Healthcare Solutions, Inc. $1,056 36 payments
  6. Ethicon Inc. $697 23 payments
  7. Actelion Pharmaceuticals US, Inc. $586 33 payments
  8. Genzyme Corporation $580 22 payments
  9. Grifols USA, LLC $551 28 payments
  10. Paratek Pharmaceuticals, Inc. $488 24 payments
  11. Other $3,859 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,024 863 payments
  2. Education $103 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,995 131 payments
  2. GLASSIA $1,639 78 payments
  3. FASENRA $1,193 41 payments
  4. BREZTRI $1,039 26 payments
  5. AIRSUPRA $911 29 payments
  6. SPIRIVA RESPIMAT $840 43 payments
  7. TEZSPIRE $743 19 payments
  8. NUCALA $668 53 payments
  9. STIOLTO RESPIMAT $667 33 payments
  10. DUPIXENT $662 22 payments
  11. Other $10,373 525 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

3,416

Median for Pulmonary Disease: 936

Drug cost

$2,258,654

Median for Pulmonary Disease: $487,987

Branded share of claims

72.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 966 $853,229
Ofev Nintedanib Esylate Brand 68 $801,145
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 435 $335,742
Breo Ellipta Fluticasone/Vilanterol Brand 119 $74,138
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 63 $37,797
Spiriva Respimat Tiotropium Bromide Brand 34 $31,896
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 42 $28,385
Eliquis Apixaban Brand 23 $15,971
Symbicort Budesonide/Formoterol Fumarate Brand 47 $15,276
Sunosi Solriamfetol Hcl Brand 13 $13,060

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$367,354

Medicare's payments for the services billed

Medicare patients

1,360

Average age 76

Services billed

4,478

663 women, 697 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 63%
Ischemic heart disease 59%
Arthritis 56%
Chronic kidney disease 47%
Heart failure 41%
Atrial fibrillation 40%
Diabetes 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $304
  • Regeneron Healthcare Solutions, Inc. $276
$580 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $444
$444 966 —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $309
$309 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $225
$225 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $219
$219 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

866 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record